Pneumagen develops glycan targeted carbohydrate binding modules (CBMs) for respiratory tract infections ) and cancer.
Pneumagen has raised €9.1M across 2 funding rounds from 2 investors, most recently a round in Jan 2022. Based in Saint Andrews, UK; founded 2016; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum flat. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2022-01-19 | Other | €4.6M | Scottish Enterprise,Thairm Bio | View deal → |
| 2020-05-27 | Early VC | €4.5M | Thairm Bio | View deal → |
